Cellier, M.; Bourneau-Martin, D.; Abbara, C.; Crosnier, A.; Lagarce, L.; Garnier, A.-S.; Briet, M.
Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase®, the WHO Pharmacovigilance Database. Cancers 2023, 15, 2041.
https://doi.org/10.3390/cancers15072041
AMA Style
Cellier M, Bourneau-Martin D, Abbara C, Crosnier A, Lagarce L, Garnier A-S, Briet M.
Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase®, the WHO Pharmacovigilance Database. Cancers. 2023; 15(7):2041.
https://doi.org/10.3390/cancers15072041
Chicago/Turabian Style
Cellier, Morgane, Delphine Bourneau-Martin, Chadi Abbara, Alexandre Crosnier, Laurence Lagarce, Anne-Sophie Garnier, and Marie Briet.
2023. "Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase®, the WHO Pharmacovigilance Database" Cancers 15, no. 7: 2041.
https://doi.org/10.3390/cancers15072041
APA Style
Cellier, M., Bourneau-Martin, D., Abbara, C., Crosnier, A., Lagarce, L., Garnier, A.-S., & Briet, M.
(2023). Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase®, the WHO Pharmacovigilance Database. Cancers, 15(7), 2041.
https://doi.org/10.3390/cancers15072041